Aligos Therapeutics/$ALGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Ticker
$ALGS
Sector
Primary listing
Employees
82
Headquarters
Website
ALGS Metrics
BasicAdvanced
$35m
-
-$8.70
2.27
-
Price and volume
Market cap
$35m
Beta
2.27
52-week high
$13.69
52-week low
$4.80
Average daily volume
93k
Financial strength
Current ratio
2.557
Quick ratio
2.354
Long term debt to equity
2.073
Total debt to equity
13.693
Profitability
EBITDA (TTM)
-94.589
Gross margin (TTM)
-1,378.77%
Net profit margin (TTM)
-1,919.68%
Operating margin (TTM)
-2,033.39%
Effective tax rate (TTM)
-0.66%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-55.56%
Return on equity (TTM)
-121.86%
Valuation
Price to revenue (TTM)
12.337
Price to book
1.09
Price to tangible book (TTM)
1.09
Price to free cash flow (TTM)
-0.681
Free cash flow yield (TTM)
-146.76%
Free cash flow per share (TTM)
-8.204
Growth
Revenue change (TTM)
43.88%
Earnings per share change (TTM)
-48.41%
3-year revenue growth (CAGR)
-30.57%
3-year earnings per share growth (CAGR)
-43.69%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs